LADARVision Gets Panel Nod For LASIK Hyperopia Correction With Conditions
This article was originally published in The Gray Sheet
Executive Summary
Laser-assisted in situ keratomileusis (LASIK) labeling for Autonomous Technologies Corp.' s LADARVision ophthalmic excimer laser system should highlight declining predictability of outcome in patients with a pre-operative manifest refractive spherical equivalance (MRSE) or uncorrected visual acuity (UCVA) greater than +/-4 diopters.
You may also be interested in...
Alcon Eye Laser Hyperopia With Astigmatism Approval Provides Edge, For Now
FDA approval of Alcon Summit Autonomous' LADARVision device for laser-assisted in situ keratomileusis (Lasik) treatment of hyperopia with or without astigmatism, and for mixed astigmatism, gives the firm an exclusive market niche, if only temporarily.
Alcon Eye Laser Hyperopia With Astigmatism Approval Provides Edge, For Now
FDA approval of Alcon Summit Autonomous' LADARVision device for laser-assisted in situ keratomileusis (Lasik) treatment of hyperopia with or without astigmatism, and for mixed astigmatism, gives the firm an exclusive market niche, if only temporarily.
Alcon Entering Refractive Laser Surgery Market Via $890 Mil. Summit Buy
Alcon Labs' $890 mil. cash purchase of ophthalmic excimer laser manufacturer Summit Autonomous will place it on a level playing field with competitor Bausch & Lomb, which already competes in the eye laser market. The definitive deal was announced May 26.